Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1411685 · FYE Mar 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $0.23Day +1.13%Mkt cap $10M1Y −92.7%Off 52W high −95.5%Vol (1Y) 133.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,557 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.9% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+2.65% |
| Top-10 13F concentration76.7% |
| Next report (est.)2026-09-19 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.3M |
| Earnings (TTM)-$69.7M |
| ROE−131.6% |
| Net margin−5491.3% |
| ROIC−1426.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−64.7% |
| 1Y−92.7% |
| 3Y−87.1% |
| 5Y−99.7% |
| 10Y−99.8% |
| Since incept. (ann.)−48.5% |
Total return through 2026-07-28 · series begins 2016-05-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)133.0% |
| Ann. volatility (3Y)405.2% |
| Sharpe (1Y)−0.77 |
| Sharpe (3Y)0.41 |
| Max drawdown (1Y)−95.4% |
| Max drawdown (3Y)−98.3% |
| Beta (3Y vs SPY)0.31 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 3.1M | $2M | 7.46% | +0.0% |
| TCG Crossover Management, LLC | 2.7M | $2M | 6.52% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $900,442 | 3.84% | new |
| ADAR1 Capital Management, LLC | 751,141 | $429,277 | 1.83% | +20.5% |
| ACADIAN ASSET MANAGEMENT LLC | 589,663 | $336,000 | 1.44% | new |
| Ikarian Capital, LLC | 519,077 | $296,654 | 1.27% | +0.0% |
| TWO SIGMA INVESTMENTS, LP | 469,619 | $268,387 | 1.14% | +140.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 453,391 | $259,170 | 1.10% | +28.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-06-15 | — | — | $464,000 | — |
| 2025-12-31 | 2026-02-12 | −$0.45 | — | $303,000 | +29.5% |
| 2025-09-30 | 2025-11-13 | −$0.54 | — | $258,000 | +41.0% |
| 2025-06-30 | 2025-08-07 | −$0.47 | — | $244,000 | +190.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-09-19 is ESTIMATED from filing cadence (median gap 96d) — not company-confirmed.
